Clinical Trial Finder

Inclusion Criteria:

This study plans to enroll approximately 500 patients with IPF/SSc-ILD/PF-ILD who newly initiate nintedanib per physicians' discretion within 6 months before participating in the study. IPF cohort:

• - Diagnosed with IPF during the prior 6 months before study enrollment, based on the 2018 ATS/ERS/JRS/ALAT guideline.

• - Patient ≥ 40 years of age.

• - Newly initiating nintedanib within 6 months prior to participating in the study.

• - Providing written informed consent prior to participating in the study.

• - Having further follow-up possibility with participating physician during the planned study period.

• - Ability to read and write in local language.

SSc-ILD cohort:

• - Diagnosed with SSc-ILD during the prior 6 months before study enrollment, based on 2013 ACR/EULAR.

• - Patient ≥ 20 years of age.

• - Newly initiating nintedanib OR not receiving nintedanib per physician's discretion (For patients who diagnosed with SSc-ILD but are not treated with nintedanib on physician's discretion, they will apply the same inclusion criteria, with baseline characteristics collected only) within 6 months prior to participating in the study.

• - Providing written informed consent prior to participating in the study.

• - Having further follow-up possibility with participating physician during the planned study period.

• - Ability to read and write in local language.

PF-ILD cohort:

• - Diagnosed with PF-ILD (PF-ILD patients will be enrolled only after nintedanib acquires the label approval from TFDA) during the prior 6 months before study enrollment.

The definition of PF-ILD diagnosis is as follows: --Patients who have ILD with a progressive phenotype, but are not diagnosed with IPF, per physician's judgment. The pathophysiology in these patients is characterized by self-sustaining fibrosis and a deterioration in lung function over time, with worsening respiratory symptoms, resistance to immune-modulatory therapies, and ultimately early mortality.

• - Patient ≥ 20 years of age.

• - Newly initiating nintedanib OR not receiving nintedanib per physician's discretion (For patients who diagnosed with PF-ILD but are not treated with nintedanib on physician's discretion, they will apply the same inclusion criteria, with baseline characteristics collected only) within 6 months prior to participating in the study.

• - Providing written informed consent prior to participating in the study.

• - Having further follow-up possibility with participating physician during the planned study period.

• - Ability to read and write in local language.

Exclusion Criteria:

• - Lung transplantation expected within the next 6 months.

--Included in ongoing interventional trials

Arms

: Idiopathic Pulmonary Fibrosis (IPF)

: Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

: Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)

Interventions

Drug: - OFEV®

nintedanib